Varivax (varicella) Market Report 2026

Varivax (varicella) Market Overview

• The Varivax (varicella) market growth in the historic period has been driven by frequent chickenpox outbreaks, pediatric vaccination schedules • Market expansion is supported by growth of mmrv vaccine usage, expansion of adult immunization programs • Growth Driver: Growing Immunization Programs To Accelerate The Expansion Of The Varivax (varicella) Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Varivax (varicella) Market?

Varivax (varicella) refers to a vaccine used to protect against varicella, which is caused by the varicella-zoster virus. This live attenuated vaccine stimulates the immune system to develop immunity, preventing the disease or reducing its severity in case of exposure. The main products in the varivax (varicella) market are monovalent varicella vaccine and combination varicella vaccine. A monovalent varicella vaccine is a single-component vaccine designed specifically to protect against varicella (chickenpox) caused by the varicella-zoster virus. The various clinical indications including chickenpox immunization, herpes zoster immunization, and mumps, measles, rubella and varicella (MMRV) immunization, and several end uses including hospitals, clinics, ambulatory care, and home care.

What Is The Varivax (varicella) Market Growth Forecast?

The growth in the forecast period can be attributed to growth of mmrv vaccine usage, expansion of adult immunization programs, stronger disease surveillance systems, increasing healthcare investments, improved vaccine accessibility. Major trends in the forecast period include expansion of routine childhood immunization, growing adoption of combination vaccines, government mandated vaccination programs, improvements in vaccine cold chain systems, rising awareness of preventable viral diseases.

Global Varivax (varicella) Market Segmentation

1) By Product: Monovalent Varicella Vaccine, Combination Varicella Vaccine 2) By Clinical Indication: Chickenpox Immunization, Herpes Zoster Immunization, Mumps, Measles, Rubella And Varicella (MMRV) Immunization 3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care

What Are The Drivers Of The Varivax (varicella) Market?

The increasing immunization programs are expected to propel the growth of the varivax (varicella) market going forward. Immunization programs are structured public health initiatives designed to protect individuals and populations from infectious diseases by administering vaccines. The increasing immunization programs are due to the growing recognition of their effectiveness in preventing the spread of infectious diseases, the expansion of global vaccination coverage, advancements in vaccine technology, heightened awareness of public health risks, and the push for greater protection of vulnerable populations, including infants, elderly individuals, and those with compromised immune systems. Immunization programs support varivax (varicella) by facilitating its widespread distribution and administration, ensuring high vaccination coverage, which in turn promotes herd immunity, reduces the incidence of chickenpox, and helps protect vulnerable populations from the complications associated with the disease. For instance, in January 2024, according to the National Health Service, a UK-based government agency, initiated NHS vaccine strategy for immunization goals. The strategy includes plans for community-based vaccination services, particularly targeting underserved and marginalized groups. Multidisciplinary teams will be deployed to improve access and outreach. Therefore, increasing immunization programs drives the varivax (varicella) industry. The increasing birth rates are expected to propel the growth of the varivax (varicella) market going forward. Birth rates refer to the number of live births occurring in a specific population during a given time period, typically expressed as the number of births per 1,000 people per year. The increase in birth rates is due to various factors, including improved healthcare, government incentives, and changing societal attitudes. Varivax (varicella), by preventing the onset of chickenpox, reduces the risk of complications during pregnancy, such as congenital varicella syndrome, which can negatively impact fetal health and birth outcomes, thereby indirectly contributing to healthier pregnancies and potentially supporting improved birth rates. For instance, in October 2024, according to the Australian Bureau of Statistics, an Australia-based government agency, there were 24,737 Aboriginal and Torres Strait Islander births registered in 2023, an increase of 349 babies from 2022. Thus, increasing birth rates are driving the growth of the varivax (varicella) industry. The rise in healthcare expenditure is expected to propel the growth of the varivax (varicella) market going forward. Healthcare expenditure is attributed to the financial investment made by governments, private insurers, and individuals in the healthcare system to improve and expand medical services. Healthcare expenditure supports varivax (varicella) by reducing healthcare costs associated with treating chickenpox and its complications, thereby promoting long-term public health savings and encouraging broader access to vaccinations, which ultimately enhances overall community health outcomes. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare expenditure is driving the growth of the varivax (varicella) industry.

Key Players In The Global Varivax (varicella) Market

Major companies operating in the varivax (varicella) market are Merck & Co. Inc.

Regional Insights

North America was the largest region in the Varivax (varicella) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Varivax (varicella) Market?

The varivax (varicella) market consists of sales of MMRV (measles, mumps, rubella, and varicella)vaccine and multivalent combinations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Varivax (varicella) Market Report 2026?

The varivax (varicella) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the varivax (varicella) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.